23
Participants
Start Date
February 28, 2011
Primary Completion Date
April 30, 2016
Study Completion Date
April 30, 2017
Lapatinib and RAD-001
"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
University of Kansas Medical Centner, Kansas City
Collaborators (2)
Novartis
INDUSTRY
GlaxoSmithKline
INDUSTRY
University of Kansas Medical Center
OTHER